Does Atopic Dermatitis Pose an Increased Risk of Acquiring COVID-19?

Does Atopic Dermatitis Pose an Increased Risk of Acquiring COVID-19?

Doug Brunk

December 27, 2021

0

According to the best available evidence, patients with atopic dermatitis (AD) do not appear to face an increased risk of acquiring COVID-19 or becoming hospitalized because of the virus.

"This is an area that will continue to evolve, and further understanding will improve the healthcare advice that we provide to our patients," Jacob P. Thyssen, MD, PhD, DmSci, said at the Revolutionizing Atopic Dermatitis virtual symposium. "The general recommendation for now is to continue systemic AD treatments during the pandemic, but the risk of acquiring COVID-19 is different for different drugs."

According to Thyssen, professor of dermatology at the University of Copenhagen, Denmark, early management guidance from the European Task Force on Atopic Dermatitis (ETFAD), the European Academy of Allergy and Clinical Immunology (EAACI), and the International Eczema Council (IEC) state that patients with AD who are on biologics or immunosuppressants should continue treatment if they are not infected with COVID-19. For example, the EIC statement says that the IEC "does not recommend temporary interruption of systemic AD treatments affecting the immune system in patients without COVID-19 infection, or in those who have COVID-19 but are asymptomatic or have only mild symptoms."

Guidelinesfrom the EAACI recommend that patients with AD who become infected with COVID-19 withhold biologic treatment for a minimum of 2 weeks until they have recovered and/or have a negative SARS-CoV-2 test.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....